[Home ] [Archive]   [ فارسی ]  
:: Main :: About us :: Current Issue :: Archive :: Search :: Submit :: Contact ::
Main Menu
Home::
Journal Information::
Articles archive::
For Authors::
For Reviewers::
Subscription::
News& Events::
Contact us::
Site Facilities::
::
Search in website

Advanced Search
..
Receive site information
Enter your Email in the following box to receive the site news and information.
..
Indexing
                        
..
:: Volume 11, Issue 2 (Summer 2014) ::
Sci J Iran Blood Transfus Organ 2014, 11(2): 126-136 Back to browse issues page
Enrichment of phage display library against breast cancer cells for isolation of anti-HER2 camelid single domain antibodies
F. Rahimi Jamnani , F. Rahbarizadeh , M.A. Shokrgozar , D. Ahmadvand , F. Mahboudi
Keywords: Key words : Genes ٬ HER-2, Breast Cancer
Full-Text [PDF 397 kb]   (2327 Downloads)     |   Abstract (HTML)  (8135 Views)
Type of Study: Research | Subject: Hematology and Oncology
Published: 2014/06/22
Full-Text:   (1595 Views)
References :
  1. Yarden Y, Pines G. The ERBB network: at last, cancer therapy meets systems biology. Nat Rev Cancer 2012; 12(8): 553-63.
  2. Emde A, Emde A, Köstler WJ, Yarden Y; Association of Radiotherapy and Oncology of the Mediterranean arEa (AROME). Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Crit Rev Oncol Hematol 2012; 84 Suppl 1: e49-57.
  3. Moasser MM. Targeting the function of the HER2 oncogene in human cancer therapeutics. Oncogene 2007; 26(46): 6577-92.
  4. Cho HS, Mason K, Ramyar KX, Stanley AM, Gabelli SB, Denney DW Jr, et al. Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 2003; 421(6924): 756-60.
  5. Wolf-Yadlin A, Kumar N, Zhang Y, Hautaniemi S, Zaman M, Kim HD, et al. Effects of HER2 overexpression on cell signaling networks governing proliferation and migration. Mol Syst Biol 2006; 2: 54.
  6. Baker M. Upping the ante on antibodies. Nat Biotechnol 2005; 23(9): 1065-72.
  7. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy--revisited. Nat Rev Drug Discov 2011; 10(8): 591-600.
  8. Kolkman JA, Law DA. Nanobodies – from llamas to therapeutic proteins. Drug Discovery Today Technol 2010; 7(2): 139-46.
  9. Rahbarizadeh F, Rahimi jamnani F, Iri-Sofla FJ. Nanobody, New Agent for Combating Against Breast Cancer Cells. In: Gunduz E, Gunduz M. Breast Cancer - Current and Alternative Therapeutic Modalities. Rijeka: InTech; 2011. p. 347-70.
  10. Rahimi Jamnani F, Rahbarizadeh F, Shokrgozar MA. Nanobodies: Promising Nanodevices for Immunotherapy. Nanotechnology  2011; 160  (11):  36-41. [Article in Farsi]
 
  1. Behdani M, Zeinali S, Khanahmad H, Karimipour M, Asadzadeh N, Azadmanesh K, et al. Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor. Mol Immunol 2012; 50(1-2): 35-41.
  2. Ahmadvand D, Rasaee MJ, Rahbarizadeh F, Kontermann RE, Sheikholislami F. Cell selection and characterization of a novel human endothelial cell-specific nanobody. Mol Immunol 2009; 46(8-9): 1814-23.
  3. Tse C, Gauchez AS, Jacot W, Lamy PJ. HER2 shedding and serum HER2 extracellular domain: biology and clinical utility in breast cancer. Cancer Treat Rev 2012; 38(2): 133-42.
  4. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 2001; 61(12): 4744-9.
  5. Wang J, Willumsen N, Zheng Q, Xue Y, Karsdal MA, Bay-Jensen AC. Bringing cancer serological diagnosis to a new level: focusing on HER2, protein ectodomain shedding and neoepitope technology. Future Oncol 2013; 9(1): 35-44.
  6. Rahbarizadeh F, Rasaee MJ, Forouzandeh M, Allameh A, Sarrami R, Nasiry H, et al. The production and characterization of novel heavy-chain antibodies against the tandem repeat region of MUC1 mucin. Immunol Invest 2005; 34(4): 431-52.
  7. Ahmadvand D, Rasaee MJ, Rahbarizadeh F, Mohammadi M. Production and characterization of a high-affinity nanobody against human endoglin.
Hybridoma (Larchmt) 2008; 27(5): 353-60.
  1. Beatty JD, Beatty BG, Vlahos WG. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J Immunol Methods 1987; 100(1): 173-9.
  2. Jamnani FR, Rahbarizadeh F, Shokrgozar MA, Ahmadvand D, Mahboudi F, Sharifzadeh Z. Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells. Exp Cell Res 2012; 318(10): 1112-24.
  3. Jamnani FR, Rahbarizadeh F, Shokrgozar MA, Mahboudi F, Ahmadvand D, Sharifzadeh Z, et al. T cells expressing VHH-directed oligoclonal chimeric HER2 antigen receptors: Towards tumor-directed oligoclonal T cell therapy. Biochim Biophys Acta 2014; 1840(1): 378-86.
  4. Rahbarizadeh F, Rasaee MJ, Forouzandeh Moghadam M, Allameh AA, Sadroddiny E. Production of novel recombinant single-domain antibodies against tandem repeat region of MUC1 mucin. Hybrid Hybridomics 2004; 23(3): 151-9.
  5. Haurum JS. Recombinant polyclonal antibodies: the
    next generation of antibody therapeutics? Drug Discov Today 2006; 11(13-14): 655-60.
  6. Ben-Kasus T, Schechter B, Lavi S, Yarden Y, Sela M. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proc Natl Acad Sci U S A 2009; 106(9): 3294-9.
  7. Vaneycken I, Devoogdt N, Van Gassen N, Vincke C, Xavier C, Wernery U, et al. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB J 2011; 25(7): 2433-46.
  8. Sheikholeslami F, Rasaee MJ, Shokrgozar MA, Dizaji MM, Rahbarizadeh F, Ahmadvande D. Isolation of a Novel Nanobody Against HER-2/neu Using Phage Displays Technology. Lab Medicine 2010; 41(2): 69-76.
  9. Zagozdzon R, Gallagher WM, Crown J. Truncated HER2: implications for HER2-targeted therapeutics. Drug Discov Today 2011; 16(17-18): 810-6.
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Original Article
 
 
 
Sci J Iran Blood Transfus Organ 2014; 11(2): 126-136
 
 
 
 
 


Enrichment of phage display library against breast
 cancer cells for isolation of anti-HER2 camelid single
domain antibodies
 
Rahimi Jamnani F.1, Rahbarizadeh F.2, Shokrgozar M.A.3, Ahmadvand D.4, Mahboudi F.1
 
 
1Biotechnology Research Center, Pasteur Institute of Iran, Tehran, Iran
2Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
3National Cell Bank of Iran, Pasteur Institute of Iran, Tehran, Iran
4School of Allied Medical Sciences, Tehran University of Medical Sciences, Tehran, Iran
 
Abstract
Background and Objectives
Breast cancer cells can be hidden from immune cells by shedding tumor markers such as HER2. The increased soluble HER2 (sHER2) concentrations are associated with the outcome of HER2-positive breast cancer and sensitivity to trastuzumab treatment. To this end, camelid single domain antibodies (VHH) with unique properties and binding ability are very striking targeting agents to detect sHER2.
 
Materials and Methods
By panning on HER2 negative and positive cells, an immune camel library was enriched against HER2 antigen. Affinity and specificity of four selected VHHs to HER2, detection of sHER2 and binding of selected VHHs to HER2 on breast cancer cells were investigated by ELISA.
 
Results
After cell panning and ELISA, four VHHs that recognized HER2 antigen better than negative control were identified. High affinity HER2 specific VHHs (1012-1013 M-1) were able to detect sHER2 (2 µg/ml). When the mixture of VHH and sMUC1 was added to HER2 coated-well, the VHH bound to HER2. RR4 and RR6 VHHs showed the highest binding to SKBR3 (HER2 expressing cell) (2±0.33 and 2.5±0.15, respectively) compared to HER2 negative cell (0.38 ± 0.17 and 0.4±0.12, respectively).
 
Conclusions
The HER2 status of a primary tumor and responses to treatment can be evaluated by measuring sHER2 as a biomarker by HER2 specific VHHs.
 
Key words: Genes٬ HER-2, Breast Cancer
 
 
 
 
 
Received: 20 May 2013
Accepted:  9 Dec  2013
 
 
 

Correspondence: Rahberizadeh F., PhD of Medical Biochemistry. Associate Professor of Medical Biotecnology. Department of Medical Biotechnology, Faculty of Medical Sciences, Tarbiat Modares University.
P.O. Box: 14115-331, Tehran, Iran. Tel: (+9821) 82883884 ; Fax: (+9821) 88013030
E-mail:
Rahbarif@modares.ac.ir
Send email to the article author

Add your comments about this article
Your username or Email:

CAPTCHA


XML   Persian Abstract   Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rahimi Jamnani F, Rahbarizadeh F, Shokrgozar M, Ahmadvand D, Mahboudi F. Enrichment of phage display library against breast cancer cells for isolation of anti-HER2 camelid single domain antibodies . Sci J Iran Blood Transfus Organ 2014; 11 (2) :126-136
URL: http://bloodjournal.ir/article-1-755-en.html


Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 11, Issue 2 (Summer 2014) Back to browse issues page
فصلنامه پژوهشی خون Scientific Journal of Iran Blood Transfus Organ
The Scientific Journal of Iranian Blood Transfusion Organization - Copyright 2006 by IBTO
Persian site map - English site map - Created in 0.05 seconds with 39 queries by YEKTAWEB 4645